Scarica l'app Stockscreener
137.49
0.00%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$137.34
Aprire:
$136.8
Volume 24 ore:
1.13M
Relative Volume:
0.16
Capitalizzazione di mercato:
$170.77B
Reddito:
$29.45B
Utile/perdita netta:
$8.51B
Rapporto P/E:
20.27
EPS:
6.7823
Flusso di cassa netto:
$9.46B
1 W Prestazione:
-4.89%
1M Prestazione:
-6.98%
6M Prestazione:
+20.82%
1 anno Prestazione:
+28.67%
Intervallo 1D:
$136.47
$137.75
Intervallo di 1 settimana:
$136.44
$143.79
Portata 52W:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.56 | 170.50B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
900.74 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.03 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.22 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
115.70 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
184.10 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Bernstein reiterates Gilead stock rating on Ouro acquisition - Investing.com
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
Gilead Chief Gets 20% Pay Bump, Still Falls Short of $30M Club - BioSpace
Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos - BioSpace
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset’ Is Key to Future Gains. - Barron's
Goldman Sachs reiterates Neutral on Gilead stock after Ouro deal - Investing.com
Gilead to Acquire Ouro Medicines in Over $2 Billion Deal - eHealth Magazine
This pharma company’s twice-yearly shot is putting the end of HIV/AIDS within reach - Fast Company
E. Ohman J or Asset Management AB Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos - Fierce Biotech
Gilead Sciences (GILD) Acquires Ouro Medicines for $1.675 Billio - GuruFocus
Gilead nearing $2B takeout of Ouro: report - FirstWord Pharma
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases (GILD:NASDAQ) - Seeking Alpha
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth - TipRanks
Keymed Biosciences shares rise on $320 mln windfall from Gilead-Ouro deal - Investing.com
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - Stocktwits
Gilead snags another local company, this one launched little more than a year ago - The Business Journals
Gilead boosts immunology pipeline with over $2 billion buyout of Ouro Medicines - KELO-AM
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets - WSJ
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports By Reuters - Investing.com
Gilead (GILD) Expands Portfolio with Acquisition of Ouro Medicines - GuruFocus
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal By Reuters - Investing.com
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - AOL.com
Gilead to buy Ouro Medicines for up to $2.2 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Gilead Sciences to acquire Ouro Medicines in push for autoimmune disease therapies - Traders Union
Gilead to buy Ouro Medicines for up to $2.2 billion - Investing.com
Gilead to acquire Ouro Medicines for up to $2.18 billion By Investing.com - Investing.com India
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewswire Inc.
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases - TradingView
Gilead to Buy Ouro Medicines for Its Autoimmune Drugs - Bloomberg.com
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases - Business Wire
Gilead Sciences (GILD) Nears $2 Billion Acquisition of Ouro Medi - GuruFocus
Gilead (GILD) Edges Toward $2 Billion Acquisition of Ouro Medici - GuruFocus
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports - Yahoo Finance
Gilead Sciences nears $2 billion Ouro Medicines acquisition - Investing.com South Africa
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports - marketscreener.com
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines - Financial Times
Gilead boss' compensation jumped 20% last year to $28.4 million - The Business Journals
Weekly Recap: Should I set a stop loss on Gilead Sciences Inc2026 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Gilead Sciences to Buy Arcellx in $7.8B Deal to Strengthen Cell Therapy Portfolio - The Healthcare Technology Report.
Stock Recap: What is the next catalyst for Gilead Sciences Inc2026 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
GILD.SW Gilead Sciences SIX up 70.33% pre-market 23 Mar 2026: valuation risk - Meyka
Arcellx earnings on deck ahead of Gilead acquisition close - Investing.com
Nordea Investment Management AB Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
New England Research & Management Inc. Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
IAM Advisory LLC Takes $1.27 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BCGM Wealth Management LLC Invests in Gilead Sciences - National Today
BCGM Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Here is what to know beyond why Gilead Sciences, Inc. (GILD) is a trending stock - MSN
Former Gilead Sciences GC To Earn Over $2.5M Severance - Law360
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Mar 16 '26 |
Sale |
144.23 |
3,000 |
432,690 |
179,191 |
0.31%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):